<DOC>
	<DOC>NCT01652820</DOC>
	<brief_summary>Randomized study in 2 arms, without any masking in patients with non small cell lung cancer, histologically or cytologically confirmed, not liable to surgery, stage IIIB or IIIA, according to the TNM classification of the American Joint Committee for cancer. In one arm will be administered concomitant radiotherapy and carboplatin-docetaxel-gemcitabine followed by docetaxel and, in the other arm will be administered docetaxel-gemcitabine followed by concurrent radiotherapy with carboplatin-docetaxel</brief_summary>
	<brief_title>Chemotherapy/Radiotherapy Versus Concomitant Chemotherapy Followed by Radiotherapy in Stage IIIB Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Unresectable stage IIIA or B NSCLC patients WHO PS 0 or 1 Weight loss &lt; 5 % within the last 3 months At least one measurable lesion Planning CT scan previous to randomization Written informed consent Malignant effusion, supraclavicular node or SVCS PTV &gt; 2000 cm3 V20 &gt; 35% FEV1 and DLCO both &lt; 30% or 1 liter at study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>LUNG</keyword>
	<keyword>DOCETAXEL</keyword>
	<keyword>GEMCITABINE</keyword>
	<keyword>CARBOPLATIN</keyword>
	<keyword>RADIOTHERAPY</keyword>
</DOC>